<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Hardy | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/markchess88/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/markchess88/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Hardy.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">a1f3b483be0158c18519e3bdd7e00c45</guid>
				<title>Hardy posted an update: Introduction Cancer drug therapy costs continue to rise and [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38494/</link>
				<pubDate>Tue, 04 Feb 2025 11:45:06 -0800</pubDate>

									<content:encoded><![CDATA[<p>Introduction Cancer drug therapy costs continue to rise and threaten the sustainability of Canada&#8217;s public healthcare system. Previous studies have calculated potential savings utilizing different dosing regimens of cancer treatments. Our objectives were to determine the financial impact of drug wastage and to explore cost-effective dosing&hellip;<span class="activity-read-more" id="activity-read-more-38494"><a href="http://www.nationalboardinstitute.com/activity/p/38494/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7b97f789408cbe01bdc9cbb87a98b676</guid>
				<title>Hardy posted an update: We applied single-factor and multiple-factor analyses to [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36550/</link>
				<pubDate>Sun, 02 Feb 2025 11:12:48 -0800</pubDate>

									<content:encoded><![CDATA[<p>We applied single-factor and multiple-factor analyses to explore the driving mechanisms of DSF at the 10-day scale. Among single factors, a low wind-speed threshold, high solar radiation, and high evaporation were correlated with a high DSF, effectively explaining the variations in DSF at the 10-day scale; however, temperature, relative humidity,&hellip;<span class="activity-read-more" id="activity-read-more-36550"><a href="http://www.nationalboardinstitute.com/activity/p/36550/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d0c86d00223f06b5614ccbc8b964898a</guid>
				<title>Hardy posted an update: Ginkgo biloba extract possess several promising biological [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34830/</link>
				<pubDate>Fri, 31 Jan 2025 11:42:45 -0800</pubDate>

									<content:encoded><![CDATA[<p>Ginkgo biloba extract possess several promising biological activities; currently, it is clinically employed in the management of several diseases. This research work aimed to extrapolate the antioxidant and anti-inflammatory effects of Ginkgo biloba (Gb) in methotrexate (MTX)-induced liver toxicity model. These effects were analyzed using&hellip;<span class="activity-read-more" id="activity-read-more-34830"><a href="http://www.nationalboardinstitute.com/activity/p/34830/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6875b0d43e7d71c5a4db113664ad525d</guid>
				<title>Hardy posted an update: MRA prescription was not retained in the model. In [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/33917/</link>
				<pubDate>Thu, 30 Jan 2025 11:14:55 -0800</pubDate>

									<content:encoded><![CDATA[<p>MRA prescription was not retained in the model. In multivariable analyses, HK at baseline was independently associated with MRA non-prescription at baseline and subsequent discontinuation. When considering subsequent discontinuation of RAASi (instead of baseline use), HK was no longer found associated with all-cause deaths. Importantly, all RAASi&hellip;<span class="activity-read-more" id="activity-read-more-33917"><a href="http://www.nationalboardinstitute.com/activity/p/33917/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">259be341ee9c09a1c7e01fdfb4ce220c</guid>
				<title>Hardy posted an update: OBJECTIVES To evaluate the relationship between delay to [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29426/</link>
				<pubDate>Tue, 28 Jan 2025 13:08:51 -0800</pubDate>

									<content:encoded><![CDATA[<p>OBJECTIVES To evaluate the relationship between delay to computed tomography perfusion and estimated core infarct volumes in patients with large vessel occlusion (LVO). PATIENTS AND METHODS A retrospective registry of consecutive adults &gt;18 years old who underwent CTP in clinical practice for suspected LVO within 24 h of LKN at 3 academic h&hellip;<span class="activity-read-more" id="activity-read-more-29426"><a href="http://www.nationalboardinstitute.com/activity/p/29426/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a8489dbc6e18e6a620432304c4df1362</guid>
				<title>Hardy became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/29337/</link>
				<pubDate>Tue, 28 Jan 2025 13:04:22 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>